Defining the therapeutic algorithm in patients with HR positive breast cancer - United States

Oncology
Credits:
0.50 AMA PRA Category 1 Credit(s) 0.50 ANCC Contact Hours 0.50 ACPE 0.50 Pharmacology
Launch Date:
September 11, 2024
Expiration Date:
September 11, 2025

Primary Audience:

Oncologists, Gynecologic Oncologists, Primary Care Physicians, Nurse Practitioners, Physician Assistants

Relevant Terms:

HER2+, HER2- low, TNBC mBC, Breast Cancer

Francesco Pantano MD, PHD

Campus Biomedico Roma,
Rome, Italy

Francesco Pantano is a medical oncologist and associate professor at the Campus Bio-Medico University of Rome. He obtained a degree in medicine and surgery, a specialization in medical oncology and a research doctorate in osteo-oncological pathology at the Campus Bio-Medico University of Rome. From 2012 to 2014 he carried out research abroad, as a PhD student and PostDoc, at INSERM in Lyon where he focused on the role of alpha5 integrin in the processes of bone metastasis in pre-clinical models of breast cancer.

He is currently co-head of the Translational Oncology Laboratory at the Campus Bio-Medico University where he coordinates various research projects aimed at identifying new biomarkers that do not predict the efficacy of immunotherapies and new potential therapeutic targets in advanced solid tumors. He also holds the role of Head of the Osteoncology Center and contact person for the "Breast Unit" for the Oncology UOC.

1. Assess the efficacy of new target therapy options in the management of patients with HR + early and metastatic BC with and implications for team-based and shared decision-making globally
2. Apply the most recent evidence-based recommendations when managing patients with HR+ and BRCAm+ BC, based on specific patient and tumor characteristics
3. Discuss the most recent evidence -based recommendations, guidelines, and clinical trial presentations on the role of treatment optimization for HR+/HER2- breast cancer

Title
Defining the therapeutic algorithm in patients with HR positive breast cancer

Target Audience
The initiative will target oncology clinicians in the US, Germany, Spain, Italy, and France, and specifically those actively involved in the treatment of breast cancer.

Learning Objectives

  1. Assess the efficacy and safety of treatment approaches, including antibody-drug conjugates, in the management of patients with HER2+, HER2-Low, and TNBC mBC, with and implications for team-based and shared decision-making globally
  2. Apply the most recent evidence-based recommendations when managing patients with HER2+, HER2-Low, and TNBC based on specific patient and tumor characteristics
  3. Discuss the most recent evidence -based recommendations, guidelines, and clinical trial presentations on the role of antibody-drug conjugates on the management of patients with HER2+, HER2-Low, and TNBC

Faculty

Francesco Pantano MD, PHD
Campus Biomedico Roma
Rome, Italy

Disclosures of Relevant Financial Relationships

It is the policy of AcademicCME that all faculty, instructors, and planners disclose relevant financial relationships with ineligible companies. Planners have no relevant financial relationships with ineligible companies to disclose related to this activity. Faculty have disclosed the following relevant financial relationships. All relevant financial relationships have been mitigated.

Francesco Pantano MD, PHD declared receipt of honoraria or consultation fees from AstraZeneca, Novartis, Pfizer, Eli Lilly, Daiichi Sankyo, and Gilead.

Accreditation Statement

In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation Statements

AcademicCME designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™.

AcademicCME designates this enduring material for a maximum of 0.5 CNE contact hour (0.5 CNE pharmacotherapeutic contact hours).

AcademicCME designates this continuing education activity for 0.5 contact hours (0.05 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number – JA4008190-0000-24-015-H01-P

Type of Activity: Application

For Pharmacists: Pharmacists have up to 30 days to complete the evaluation and claim credit for participation so that information can be submitted to the CPE Monitor as required. After receipt of a completed activity evaluation form, you will be provided with instructions to have your credit immediately uploaded to the CPE Monitor.

Through an agreement between the American Medical Association and the Union Européenne des Médecins Spécialistes, physicians may convert AMA PRA Category 1 Credit™ to an equivalent number of European CME Credits® (ECMECs®). These credits will be recognized by all National Accreditation Authorities in Europe with which the UEMS has a signed agreement of recognition of credits


This e-learning activity: "Defining the therapeutic algorithm in patients with HR positive breast cancer" will be submitted for accreditation by the European Accreditation Council for Continuing Medical Education (EACCME).

Scientific Seminars International Foundation adheres to guidelines of the European Accreditation Council for Continuing Medical Education (EACCME®) and all other professional organizations, as applicable, which state that programs awarding continuing education credits must be balanced, independent, objective and scientifically rigorous.
 
Scientific Seminars - Privacy Policy
 
Investigative and other uses for pharmaceutical agents, medical devices and other products (other than those uses indicated in approved product labelling/package insert for the product) may be presented in the program (which may reflect clinical experience, the professional literature or other clinical sources known to the presenter).
 
Further, all opinions and recommendations presented during the program and all program-related materials neither imply an endorsement nor a recommendation on the part of Scientific Seminars International Foundation.

Disclosures of Relevant Financial Relationships

It is the policy of AcademicCME that all faculty, instructors, and planners disclose relevant financial relationships with ineligible companies. Planners have no relevant financial relationships with ineligible companies to disclose related to this activity. Faculty have disclosed the following relevant financial relationships. All relevant financial relationships have been mitigated.

Francesco Pantano declared receipt of honoraria or consultation fees from: Astra Zeneca, Novartis, Pfizer, Lilly, Daiichi Sankyo, Gilead.

Financial Support

This activity has been supported by an independent educational grant from Daiichi Sankyo, Inc.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and Daiichi Sankyo, Inc. do not recommend the use of any agent outside of the labeled indications.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Method of Participation

In order claim to the maximum amount of credit, participants must complete the following:

  1. Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
  2. Complete the Pre-Activity Questions
  3. Read or Review the activity content.
  4. Complete the Post-Activity Test Questions and Evaluation.
  5. Learners who receive a grade of 70% or better on the Post-Activity Test Questions and complete the Evaluation will receive appropriate credit as indicated (CME, CNE, and/or CPE credit). 
  • CPE credit will be posted to the learner's CPE Monitor profile within 60 days of completion. 
  • CME and CNE credit will be issued appropriate certificate of completion. 
  • Others may request a "certificate of completion".
  1. Learners should claim only the credit commensurate with the extent of their participation in the activity.

CE Inquiries/Special Needs

For all CE inquiries or special needs, please contact admin@academiccme.com.

COURSE VIEWING REQUIREMENTS

Supported Browsers:
Microsoft Edge
Google Chrome 60 or higher
Mozilla Firefox 60 or higher
Apple Safari 11.0 or higher
For video, install the latest version of Quicktime.
Supported Phones & Tablets:
iOS 9.3 and higher
Android 7.0 (Nougat or higher)
Microsoft Windows 8
Chrome OS

 
Additional Recommendations and Requirements
Display Resolution & Color Depth Resolution
- 960 X 768 minimum
- 1024 X 768 recommended min.

Color Depth
- 8 bits (256 colors) minimum
- 16 bits (High colors) minimum
Audio - Microphone
- Speakers or headphones
- Audio recording support
Word Processing Software that can open, modify, and save documents in Rich Text Format (RTF). Microsoft Word and PowerPoint are recommended.